Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...
The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...
The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...
1d
The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and ...
Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...
If you receive a denial letter from your insurer, don’t appeal the decision before seeking legal advice, says a leading ...
Dr Sundeep Salvi: Shardul Nautiyal, Mumbai Tuesday, March 4, 2025, 08:00 Hrs [IST] Chronic obstructive pulmonary disease (C ...
Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...
OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...
2d
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
After that technology had proven its worth, the full-blown virtual hospital was launched by the Saudi ministry of health in ...
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback